证券代码：688068 证券简称：热景生物 公告编号：2025-041 北京热景生物技术股份有限公司 关于股东减持计划完成暨减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： ? 股东持有的基本情况 本次减持计划实施前，北京热景生物技术股份有限公司（以下简称"公 司"）股东青岛同程热景企业管理咨询合伙企业（有限合伙） | 股东名称 同程热景 | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 控股股东、实控人及一致行动人 | | | | | | | | √是 | | □否 | | | | 股东身份 | | | | | | | | | | | | | | 直接持股 | | 5%以上股东 | | | | □是 | | □否 | | | | | | 董事、监事和高级管理人员 | | | | | | | | | | | □是 | ...

减持计划的实施结果情况 公司于 2025 年 3 月 22 日在上海证券交易所网站（www.sse.com.cn）披露 了《北京热景生物技术股份有限公司股东减持股份计划公告》（公告编号： 2025-018）。同程热景因自身资金需求，计划通过集中竞价、大宗交易方式减持 所持有公司股份合计不超过 1,800,000 股，占公司当时总股本的 1.9465%。 证券代码：688068 证券简称：热景生物 公告编号：2025-041 北京热景生物技术股份有限公司 关于股东减持计划完成暨减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持有的基本情况 本次减持计划实施前，北京热景生物技术股份有限公司（以下简称"公 司"）股东青岛同程热景企业管理咨询合伙企业（有限合伙）（以下简称"同程热 景"）持有公司股份 4,211,357 股，占公司当时股份总数的 4.55%，股份来源于 公司首次公开发行前持有及资本公积转增股本取得，已上市流通。 近日，公司收到股东同程热景出具的《股份减持结果告知函》 ...

| 成交量 | 成交金额 | 成交价格 | 相对当日收盘折溢 | 买方营 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | 价（%） | 业部 | | | 30.00 | 3510.00 | 117.00 | -14.17 | 机构专 | 山西证券股份有限公司北京太平 | | | | | | 用 | 庄证券营业部 | | 15.00 | 1755.00 | 117.00 | -14.17 | 机构专 | 山西证券股份有限公司北京太平 | | | | | | 用 | 庄证券营业部 | | 10.09 | 1180.78 | 117.00 | -14.17 | 机构专 | 山西证券股份有限公司北京太平 | | | | | | 用 | 庄证券营业部 | | 7.20 | 842.40 | 117.00 | -14.17 | 机构专 | 山西证券股份有限公司北京太平 | | | | | | 用 | 庄证券营业部 | | 5.00 | 585.00 | 117.00 | -14.17 | 机构专 | 山西证券股份有限公司北京太平 ...

北京热景生物技术股份有限公司（以下简称"公司"）及子公司近期获得国内 医疗器械注册证/备案证 16 项，获得境外资质认证 82 项，获得化妆品备案 17 项。 相关信息如下： 证券代码：688068 证券简称：热景生物 公告编号：2025-040 北京热景生物技术股份有限公司 关于公司及子公司近期获得资质情况的自愿披露 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、获得资质的具体情况 | 序号 | 产品名称 | 注册证号 | 类别 | 发证日期 | 有效期至 | 发证机构 | | --- | --- | --- | --- | --- | --- | --- | | 1 | 吗啡头发检测试剂盒 | 国械注准 | III | 2025/05/14 | 2030/05/13 | 国家药品监督管理局 | | | （上转发光法） | 20253400943 | | | | | | 2 | β2-微球蛋白测定试剂盒 | 京械注准 | II | 2025/03/18 | 2030/03/17 | 北京市药品监督管理局 | ...

截至6月3日收盘，重组蛋白概念上涨3.64%，位居概念板块涨幅第3，板块内，45股上涨，*ST万方涨 停，诺思兰德、科兴制药、海特生物等涨幅居前，分别上涨18.82%、14.97%、13.18%。跌幅居前的有 *ST苏吴、博瑞医药、西陇科学等，分别下跌4.78%、2.48%、1.42%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 中韩自贸区 | 4.23 | 特钢概念 | -0.93 | | 细胞免疫治疗 | 3.87 | 医疗废物处理 | -0.51 | | 重组蛋白 | 3.64 | 果指数 | -0.41 | | 足球概念 | 3.56 | 无线充电 | -0.39 | | 毛发医疗 | 3.51 | 光热发电 | -0.33 | | CRO概念 | 3.41 | 深圳国企改革 | -0.24 | | 创新药 | 3.38 | F5G概念 | -0.23 | | 培育钻石 | 3.11 | 租售同权 | -0.22 | | 仿制药一致性评价 | 3.08 | 一体化压铸 | -0.21 | | 眼 ...

Company Overview - Beijing Hotgen Biotech Co., Ltd. specializes in the production of diagnostic reagents, diagnostic instruments, and biological raw materials, utilizing inner threaded copper tubes and hydrophilic aluminum foil as primary materials, which offer high heat exchange efficiency and strong corrosion resistance [1] - The company has received over 60 honors, including "Beijing Specialized and Innovative Small Giant Enterprise" and "Beijing Enterprise Technology Center," and has been recognized for its research and development achievements with multiple awards [1] Financial Performance - For Q1 2025, the company reported revenue of 93.24 million yuan, a year-on-year decrease of 19.71%, and a net loss of approximately 24 million yuan, reflecting a significant year-on-year decline of 574.96% [2] - The company's gross profit margin stands at 47.27% [2] Shareholder Information - As of March 31, 2025, the number of shareholders for Hotgen Biotech is 6,662, a decrease of 1,793 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] Market Valuation - The company's latest closing price is 124.52 yuan, with a market capitalization of 11.544 billion yuan and a price-to-book ratio of 3.87 [1] - The company's PE (TTM) is reported at -52.46, while the industry average PE is 49.65 [2]

Group 1 - The innovative drug concept stocks are experiencing a downturn, with several companies seeing declines of over 5% [1] - Notable companies affected include Sanofi, Haisun Pharmaceutical, Huisheng Biological, Rejing Biological, Haichuang Pharmaceutical, and Ruizhi Pharmaceutical [1] - Other companies such as Saiseng Pharmaceutical and Hasan Union are also following the downward trend [1]

Core Viewpoint - Beijing Hotgen Biotech Co., Ltd. is undergoing a significant transformation by diversifying into innovative drug development while facing challenges in its core in vitro diagnostic (IVD) business, leading to a mixed performance in stock price and financial results [2][3][4]. Company Overview - Founded in 2005, Hotgen Biotech specializes in in vitro diagnostic reagents and was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board in September 2019 [3]. - The company’s testing projects cover various diseases, including inflammation, cardiovascular issues, diabetes, and cancers [3]. Recent Developments - On May 22, 2024, the company held its annual shareholder meeting, discussing executive compensation, financial reports, and profit distribution [2]. - Prior to the meeting, it was announced that the controlling shareholder, Qingdao Tongcheng, reduced its stake from 28.00% to 26.99% through a share sale, raising approximately 97.03 million yuan [2]. Financial Performance - For the fiscal year 2024, the company reported a revenue of 510 million yuan, a year-on-year decrease of 6.74%, and a net loss of 191 million yuan, a significant decline of 760% [7][8]. - Despite a 26.15% growth in its magnetic microparticle chemiluminescence business, overall performance was negatively impacted by high R&D costs and losses from joint ventures [8]. Strategic Initiatives - The company is pursuing a "diagnostics + innovative drugs" dual-driven strategy, investing in strategic partnerships with innovative drug companies to develop differentiated drug pipelines focusing on antibody and nucleic acid drugs [3][4]. - Notable investments include ShunJing Pharmaceutical, which is developing a first-in-class antibody drug for acute myocardial infarction, and ZhiYuan Biotech, which is working on a monoclonal antibody for Alzheimer's disease [4][5]. Market Reaction - The stock price of Hotgen Biotech has seen significant volatility, increasing from a low of 22.94 yuan per share to a peak of 142 yuan, representing a 550% rise [4]. - The dynamic price-to-earnings ratio has surpassed that of peers in the IVD sector, despite the company's declining performance in its core business [4][6]. Investment Landscape - As of the end of last year, 143 funds held shares in Hotgen Biotech, with a total market value of 1.38 billion yuan, but this number has decreased to 52 funds holding 177.4 million shares by the first quarter of this year [10]. - The company faces increasing pressure for funding due to its cross-industry transformation and tightening regulations on refinancing in the Sci-Tech Innovation Board [7][9].

者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688068 证券简称：热景生物 公告编号：2025-039 北京热景生物技术股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 22 日 （二） 股东大会召开的地点：北京市大兴区中关村科技园区大兴生物医药产业 基地庆丰西路 55 号公司三层会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 192 | | --- | --- | | 普通股股东人数 | 192 | | 2、出席会议的股东所持有的表决权数量 | 50,696,829 | | 普通股股东所持有表决权数量 | 50,696,829 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 58.9687 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） ...

北京市朝阳区建外大街丁 12 号英皇集团中心 8、9、11 层 8/9/11/F, Emperor Group Centre, No.12D, Jianwai Avenue, Chaoyang District, Beijing, 100022, P.R.China 电话/Tel.: 010-50867666 传真/Fax: 010-56916450 网址/Website: www.kangdalawyers.com 北京市康达律师事务所 关于北京热景生物技术股份有限公司 2024 年年度股东大会的 法律意见书 康达股会字【2025】第 0127 号 二〇二五年五月 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 昆明 法律意见书 北京市康达律师事务所 关于北京热景生物技术股份有限公司 2024 年年度股东大会的法律意见书 康达股会字【2025】第0127号 致：北京热景生物技术股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券 法》（以下简称"《证券法》"）、《上市公司股东大 ...